AI Article Synopsis
- Placenta previa is a significant cause of bleeding during pregnancy and used to be a major cause of maternal deaths, but advancements in care have improved outcomes.
- It is usually detected during routine ultrasounds in the second trimester, and most cases resolve before the due date.
- Key risk factors include previous cesarean deliveries, older age, and smoking, and if the condition persists late in pregnancy, a cesarean delivery is advised.
Article Abstract
Placenta previa is an important and potentially life-threatening cause of bleeding. Historically, it was a major contributor to maternal mortality until advancements in obstetric care, including prenatal ultrasound, cesarean delivery, and transfusion medicine, drastically improved outcomes. Today, placenta previa is typically identified during routine second-trimester ultrasound, with the overwhelming majority of cases resolving before term. Key risk factors include prior cesarean delivery, advanced maternal age, and smoking. When placenta previa is diagnosed, it is essential to assess for associated conditions like placenta accreta and vasa previa. A planned cesarean delivery is recommended in cases that persist into the late third trimester.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/GRF.0000000000000911 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Takayasu's arteritis in pregnancy: A case report and literature review.
Int J Gynaecol Obstet
December 2024
Department of Obstetrics and Gynaecology, Kathmandu Medical College Public Limited, Kathmandu, Nepal.
Takayasu's arteritis (TA) is a rare, chronic inflammatory disease of unknown cause, primarily affecting young women in their reproductive years. It can result in the narrowing and occlusion of arteries and the formation of aneurysms in arteries, especially those related to the aorta, creating significant risks during pregnancy. Women with TA are more susceptible to cardiovascular complications, including hypertension and heart failure, which can negatively affect both maternal and fetal health.
View Article and Find Full Text PDFMaternal Morbidity and Medically Assisted Reproduction Treatment Types.
Obstet Gynecol
December 2024
Centre for Longitudinal Studies, Social Research Institute, University College London, London, United Kingdom; Population Science, Huntsman Cancer Institute, the Department of Family and Consumer Studies, the Department of Obstetrics and Gynecology, and the Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City; Max Planck Institute for Demographic Research, Rostock, Germany; the Helsinki Institute for Demography and Population Health, University of Helsinki, Helsinki, Finland; and the Max Planck - University of Helsinki Center for Social Inequalities in Population Health, Rostock, Germany and Helsinki, Finland.
Objective: To compare odds of maternal morbidity by mode of becoming pregnant and type of medically assisted reproduction treatments: fertility-enhancing drugs, intrauterine insemination (IUI), and assisted reproductive technology (ART) with autologous or donor oocytes.
Methods: Birth certificates were used to study maternal morbidity among the birthing population in Utah between 2009 and 2017 (N=469,919 deliveries); 22,543 pregnancies occurred through medically assisted reproduction (4.8%).
Association between obesity in women with multiple gestations and adverse obstetric outcomes: a study of an American population database with over 136,000 unique deliveries.
Arch Gynecol Obstet
December 2024
Obstetrics and Gynecology, McGill University Health Centre, Montreal, Canada.
Purpose: The purpose of this study is to compare obese and non-obese women with multiple pregnancies to determine the effects on pregnancy, delivery, and neonatal outcomes.
Methods: We conducted a retrospective population-based study utilizing data collected between 2004 and 2014 inclusively, from the Healthcare Cost and Utilization Project-Nationwide Inpatient Sample. A total of 137,303 multiple pregnancies were analyzed; 130,542 (95%) were non-obese, while 6761 (5%) were obese.
Abnormal microRNA expression profile at early stages of gestation in pregnancies destined to develop placenta previa.
Front Med (Lausanne)
December 2024
Institute for the Care of the Mother and Child, Third Faculty of Medicine, Charles University, Prague, Czechia.
Background: Placenta previa is the abnormal implantation of the placenta into the lower segment of the uterus, is associated with adverse maternal and fetal outcomes such as placenta accreta spectrum disorders, antepartum and postpartum hemorrhage, fetal growth restriction, prematurity, stillbirth and neonatal death, thrombophlebitis, and septicemia. The aim of the study was to assess retrospectively how the later onset of placenta previa affects the microRNA expression profile in the whole peripheral blood during the first trimester of gestation.
Methods: Regarding the occurrence of the association between aberrant microRNA expression profiles at early stages of gestation and later onset of various pregnancy-related complications, we selected for the study pregnancies developing placenta previa as the only pregnancy-related disorder.
Risk Factors of Marginal Cord Insertion in Singleton Pregnancies: A Systematic Review and Meta-Analysis.
J Clin Med
December 2024
Third Department of Obstetrics and Gynecology, Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki, Agiou Dimitriou, 54124 Thessaloniki, Greece.
Marginal cord insertion (MCI) is increasingly recognized as a pathological variation that necessitates early diagnosis. Identifying the risk factors associated with MCI is essential for improving prenatal screening and optimizing management strategies. Our meta-analysis systematically and quantitatively synthesizes the current evidence on various potential risk factors for MCI.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!